CRISPR Takes Another Step Forward

/in , /by

CRISPR can precisely alter DNA, but using it against cancer faces a fundamental problem: how do you deliver the genome-editing machinery to tumour cells without also editing healthy tissue? A newly published review proposes that aptamers, small synthetic DNA or RNA molecules capable of recognising specific cell-surface proteins, could provide part of the solution, guiding […]

Read more

A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response

/in , /by

A newly published study has introduced an interesting variation on antibody-drug conjugates (ADCs) for advanced prostate cancer: instead of simply delivering a toxic payload to cancer cells, the treatment is designed to help the immune system recognise what remains. The experimental ADC targets STEAP1, a cell-surface protein highly expressed in prostate cancer and already being […]

Read more

Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC

/in , , /by

A new antibody-drug conjugate has received clearance to enter clinical trials in China with a double strategy for prostate cancer: instead of targeting PSMA or STEAP1, ICP-B381 targets both. The experimental bispecific ADC combines a humanised antibody recognising PSMA and STEAP1 with a proprietary cytotoxic payload connected through an irreversible linker. Both proteins are strongly […]

Read more

Reprogramming Cancer, Decoding DNA: Two Promising New Frontiers in Cancer Research

/in , , , /by

Two important scientific developments, published last week, offer a glimpse of where prostate cancer research could be heading, even though both remain firmly in the experimental or preclinical arena. The first comes from Adelaide University, where researchers have developed “smart” lipid nanoparticles designed to reprogramme tumour-associated macrophages, immune cells that cancers can exploit to suppress […]

Read more

Drugging the Undruggable in Prostate Cancer

/in , /by

Many proteins that drive cancer are considered “undruggable” because they lack the pockets that conventional drugs need to bind and block them. A new approach in prostate cancer attempts to bypass this problem: instead of inhibiting a cancer-driving protein, make the cell destroy it. Researchers have developed a protein degrader (against an undisclosed protein) believed […]

Read more

Reading the DNA Fingerprints of Prostate Cancer

/in /by

Prostate cancer does not develop in the same way in every patient. Different biological processes can damage the DNA of cancer cells, leaving behind characteristic patterns, or “mutational signatures.” A recent study, published on Nature, used whole-genome sequencing to combine these patterns and identify eight integrated mutational footprints (IMFs), providing a broader picture of how […]

Read more

Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC

/in , , , /by

Tinengotinib (TT-00420), a multikinase inhibitor with a distinctive target profile, is showing early signals in metastatic castration‑resistant prostate cancer (mCRPC), a setting where options after modern androgen‑receptor pathway inhibitors and taxanes remain limited. Results from a US‑based, multicenter phase 1/2 trial, published in Clinical Cancer Research, reported an objective response rate of 33.3% in a […]

Read more

STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer

/in , , , , /by

A multicentre, randomised trial published in The Lancet Oncology shows that a supervised, behaviourally supported lifestyle programme can measurably blunt the adverse effects of androgen deprivation therapy (ADT) for prostate cancer. Called STAMINA, the study enrolled 700 men on ADT across 15 NHS trusts in England and randomly assigned them in a 5:4 ratio to […]

Read more